Adial Pharmaceuticals EBITDA 2011-2026 | ADIL

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Adial Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-7.8 M	-8.28 M	-6.89 M	-10.9 M	-19.3 M	-10.9 M	-8.24 M	-6.99 M	-994 K	-410 K	-817 K	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-410 K	-19.3 M	-7.41 M

Quarterly EBITDA Adial Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-2.27 M	-	-	-	-	-	-	-2.92 M	-	-3.19 M	-3.83 M	-3.06 M	-	-4.06 M	-4.4 M	-4.84 M	-	-3.34 M	-1.82 M	-2.3 M	-	-1.75 M	-2.16 M	-2.25 M	-	-3.82 M	-1.74 M	-339 K	-	-262 K	-241 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-241 K	-4.84 M	-2.56 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Ascendis Pharma A/S ASND	-452 M	$ 219.68	1.92 %	$ 5 B	Danmark
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Seres Therapeutics MCRB	-102 M	$ 8.28	-	$ 1.06 B	USA
Amphastar Pharmaceuticals AMPH	172 M	$ 19.45	1.14 %	$ 909 M	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Mesoblast Limited MESO	-78.1 M	$ 15.44	7.82 %	$ 10 B	Australia
Atreca BCEL	5.46 M	-	-11.76 %	$ 5.79 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
BeiGene, Ltd. BGNE	589 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	-216 M	-	-	$ 546 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
CollPlant Biotechnologies Ltd. CLGN	-16.2 M	$ 0.67	-5.25 %	$ 7.67 M	Israel
Mirum Pharmaceuticals MIRM	2.11 M	$ 90.39	2.86 %	$ 4.54 B	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	-234 M	$ 1.34	1.52 %	$ 342 M	Britain
MediciNova MNOV	-13.3 M	$ 1.45	-	$ 71.1 M	USA
CytomX Therapeutics CTMX	-21.2 M	$ 4.37	2.95 %	$ 603 M	USA
Cyclacel Pharmaceuticals CYCC	-12 M	-	-5.98 %	$ 34.1 M	USA
ChemoCentryx CCXI	-127 M	-	-	$ 3.74 B	USA
Aytu BioScience AYTU	-2.45 M	$ 2.69	1.37 %	$ 16.9 M	USA
Dynavax Technologies Corporation DVAX	505 K	-	-	$ 2.02 B	USA
BioDelivery Sciences International BDSI	37.3 M	-	-4.8 %	$ 255 M	USA
Enochian Biosciences ENOB	-189 M	-	-	$ 40.5 M	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Merck & Co. MRK	3.04 B	$ 117.56	1.02 %	$ 294 B	USA
Marker Therapeutics MRKR	-12.9 M	$ 1.37	8.73 %	$ 21 M	USA
Moderna MRNA	-2.86 B	$ 53.09	3.41 %	$ 20.7 B	USA
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	-37.8 M	$ 4.47	3.71 %	$ 856 M	Canada
Homology Medicines FIXX	17.3 M	-	0.77 %	$ 53.4 M	USA